Three shades of an unusual mediastinal tumour.

Thoracic SMARCA4-deficient undifferentiated tumour (SMARCA4-UT) is an unusual and aggressive tumour. While there are approximately 100 cases of this tumour reported in the literature, there are very few detailed descriptions of its cytomorphologic characteristics, and only rare cases in which primary diagnosis was made on cytologic material. Herein we present a case with a detailed description of the appearance on three specimen types: transbronchial needle aspiration (TBNA) cytology, transbronchial needle biopsy (TBNB) and effusion cytology. Thoracic SMARCA4-UT is an important diagnosis to clinch in modern pathology because of its prognostic and therapeutic implications. We discuss an integrated approach to clinching the diagnosis with reference to clinical, radiographic, morphologic and immunohistochemical features. We also discuss possible differential diagnoses, and how they can be excluded. Cytologic and/or small biopsy diagnosis is valuable in these cases as these tumours are typically not amenable to surgical resection. With the correct diagnosis, the patient may instead be a candidate for immune checkpoint inhibitors or experimental therapy targeting SWI/SNF deficiency.

[1]  S. Khader,et al.  Thoracic SMARCA4‐deficient undifferentiated tumor with associated granulomatous reaction and response to pembrolizumab , 2023, Diagnostic cytopathology.

[2]  N. Rekhtman,et al.  Diagnosis of thoracic SMARCA4‐deficient undifferentiated tumor in cytology , 2023, Cancer cytopathology.

[3]  S. Sugita,et al.  Usefulness of cell block examination for the cytological diagnosis of thoracic SMARCA4‐deficient undifferentiated tumor: A case report , 2023, Diagnostic cytopathology.

[4]  A. Thakar,et al.  Fine needle aspiration cytology of metastatic SMARCA4‐deficient sinonasal teratocarcinosarcoma: First report in literature , 2023, Diagnostic cytopathology.

[5]  M. Bui,et al.  Assessing rapid on-site evaluation (ROSE) for adequacy of endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) compared to a direct-to-cellblock approach as a response to COVID-19 pandemic , 2022, Journal of the American Society of Cytopathology.

[6]  A. Nambirajan,et al.  Recent updates in thoracic SMARCA4-deficient undifferentiated tumor. , 2021, Seminars in diagnostic pathology.

[7]  F. Le Loarer,et al.  SWI/SNF-deficient thoraco-pulmonary neoplasms. , 2021, Seminars in diagnostic pathology.

[8]  L. Bubendorf,et al.  Cytology of SMARCA4-Deficient Thoracic Neoplasms: Comparative Analysis of SMARCA4-Deficient Non-Small Cell Lung Carcinomas and SMARCA4-Deficient Thoracic Sarcomas , 2020, Acta Cytologica.

[9]  C. VandenBussche,et al.  Review of SMARCA4 (BRG1)-deficient carcinomas following a malignant pleural effusion specimen confounded by reduced claudin-4 expression. , 2020, Journal of the American Society of Cytopathology.

[10]  C. Ohbayashi,et al.  Cytopathological Features of SMARCA4-Deficient Thoracic Sarcoma: Report of 2 Cases and Review of the Literature , 2020, International journal of surgical pathology.

[11]  David R. Jones,et al.  SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  S. Pambuccian,et al.  A BAFfling liver aspirate: Metastatic high grade SMARCA4 deficient undifferentiated gastroesophageal junction carcinoma masquerading as a hematolymphoid malignancy , 2019, Diagnostic cytopathology.

[13]  S. Kuwamoto,et al.  Cytologic Features of SMARCA4-Deficient Thoracic Sarcoma: A Case Report and Comparison with Other SWI/SNF Complex-Deficient Tumors , 2018, Acta Cytologica.

[14]  N. Girard,et al.  SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas , 2015, Nature Genetics.